West Pharmaceutical Services (WST) has drawn attention after a recent 1-day share price decline of about 1%, set against a gain of nearly 24% over the past month and a return of around 29% over the past three months.

The recent 1-day share price decline sits alongside strong short-term momentum, with a 7-day share price return of 11.85% and a 1-year total shareholder return of 43.20%. However, 3 and 5-year total shareholder returns are negative, suggesting a more mixed longer-term picture as sentiment toward growth prospects and risk has shifted over time.

If this kind of rebound catches your eye, it could be a good moment to widen your search and see 33 healthcare AI stocks

With West Pharmaceutical Services trading at US$306.16 against an average analyst price target near US$344.83, investors may be asking whether the recent gains still leave upside potential or whether the market has already incorporated expectations for future growth into the current share price.

Most Popular Narrative: 9.6% Undervalued

Against a last close of $306.16, the most followed narrative suggests a fair value of about $338.57, using a 7.79% discount rate and detailed long term cash flow assumptions.

The introduction of an automated line for HVP delivery devices later in 2025 to early 2026 is expected to improve margins by driving operational efficiencies and scale, which may enhance net margins.

The strategic focus on expanding the contract manufacturing business into drug handling, which is expected to be higher margin and require lower capital intensity, could improve net margins and earnings after the initial ramp up phase.

Want the full story behind that valuation gap? The narrative leans heavily on steady revenue expansion, thicker margins and a future earnings multiple that assumes real staying power.

Result: Fair Value of $338.57 (UNDERVALUED)

However, this hinges on HVP demand and pricing holding up, while tariffs and contract manufacturing shifts could still pressure margins and unsettle earnings expectations.

Another Take: Market Multiple Flags Rich Pricing

That 9.6% upside from the most popular narrative sits alongside a very different signal. On a P/E of 44.7x versus a fair ratio of 20.3x, the Life Sciences industry at 34.9x and peers at 30x, West Pharmaceutical Services screens as expensive. Is the market already paying up for this story?

Next Steps

With sentiment split between upside potential and rich pricing, it makes sense to check the numbers yourself and decide quickly where you stand. To see what investors are optimistic about in the current data, take a closer look at the 1 key reward

Looking for more investment ideas?

If you are serious about building a stronger portfolio, do not stop at a single stock story; use targeted screeners to surface opportunities you might otherwise miss.

• Spot potential value opportunities early by scanning 56 high quality undervalued stocks that combine quality fundamentals with pricing that may not fully reflect them.
• Strengthen your focus on balance sheet resilience by checking the solid balance sheet and fundamentals stocks screener (42 results) so you can filter for financial foundations that look more robust.
• Get ahead of the crowd by reviewing the screener containing 24 high quality undiscovered gems and see which under-the-radar names currently fit your preferred criteria.

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.